494 related articles for article (PubMed ID: 23202128)
21. Transcription Factors Involved in Tumorigenesis Are Over-Represented in Mutated Active DNA-Binding Sites in Neuroblastoma.
Capasso M; Lasorsa VA; Cimmino F; Avitabile M; Cantalupo S; Montella A; De Angelis B; Morini M; de Torres C; Castellano A; Locatelli F; Iolascon A
Cancer Res; 2020 Feb; 80(3):382-393. PubMed ID: 31784426
[TBL] [Abstract][Full Text] [Related]
22. Whole-genome sequencing of recurrent neuroblastoma reveals somatic mutations that affect key players in cancer progression and telomere maintenance.
Fransson S; Martinez-Monleon A; Johansson M; Sjöberg RM; Björklund C; Ljungman G; Ek T; Kogner P; Martinsson T
Sci Rep; 2020 Dec; 10(1):22432. PubMed ID: 33384420
[TBL] [Abstract][Full Text] [Related]
23. Suppression of RIZ in biologically unfavourable neuroblastomas.
Geli J; Kiss N; Kogner P; Larsson C
Int J Oncol; 2010 Nov; 37(5):1323-30. PubMed ID: 20878080
[TBL] [Abstract][Full Text] [Related]
24. Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data.
Łastowska M; Viprey V; Santibanez-Koref M; Wappler I; Peters H; Cullinane C; Roberts P; Hall AG; Tweddle DA; Pearson AD; Lewis I; Burchill SA; Jackson MS
Oncogene; 2007 Nov; 26(53):7432-44. PubMed ID: 17533364
[TBL] [Abstract][Full Text] [Related]
25. Coffin-Siris syndrome is a SWI/SNF complex disorder.
Tsurusaki Y; Okamoto N; Ohashi H; Mizuno S; Matsumoto N; Makita Y; Fukuda M; Isidor B; Perrier J; Aggarwal S; Dalal AB; Al-Kindy A; Liebelt J; Mowat D; Nakashima M; Saitsu H; Miyake N; Matsumoto N
Clin Genet; 2014 Jun; 85(6):548-54. PubMed ID: 23815551
[TBL] [Abstract][Full Text] [Related]
26. Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression.
Lasorsa VA; Formicola D; Pignataro P; Cimmino F; Calabrese FM; Mora J; Esposito MR; Pantile M; Zanon C; De Mariano M; Longo L; Hogarty MD; de Torres C; Tonini GP; Iolascon A; Capasso M
Oncotarget; 2016 Apr; 7(16):21840-52. PubMed ID: 27009842
[TBL] [Abstract][Full Text] [Related]
27. Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival.
Bray I; Bryan K; Prenter S; Buckley PG; Foley NH; Murphy DM; Alcock L; Mestdagh P; Vandesompele J; Speleman F; London WB; McGrady PW; Higgins DG; O'Meara A; O'Sullivan M; Stallings RL
PLoS One; 2009 Nov; 4(11):e7850. PubMed ID: 19924232
[TBL] [Abstract][Full Text] [Related]
28. An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer.
Mamo A; Cavallone L; Tuzmen S; Chabot C; Ferrario C; Hassan S; Edgren H; Kallioniemi O; Aleynikova O; Przybytkowski E; Malcolm K; Mousses S; Tonin PN; Basik M
Oncogene; 2012 Apr; 31(16):2090-100. PubMed ID: 21892209
[TBL] [Abstract][Full Text] [Related]
29. Massively parallel sequencing reveals an accumulation of de novo mutations and an activating mutation of LPAR1 in a patient with metastatic neuroblastoma.
Wei JS; Johansson P; Chen L; Song YK; Tolman C; Li S; Hurd L; Patidar R; Wen X; Badgett TC; Cheuk AT; Marshall JC; Steeg PS; Vaqué Díez JP; Yu Y; Gutkind JS; Khan J
PLoS One; 2013; 8(10):e77731. PubMed ID: 24147068
[TBL] [Abstract][Full Text] [Related]
30. Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer.
Sun D; Tian L; Zhu Y; Wo Y; Liu Q; Liu S; Li H; Hou H
Mol Med; 2020 Aug; 26(1):78. PubMed ID: 32791957
[TBL] [Abstract][Full Text] [Related]
31. The Chromatin Remodeling Component Arid1a Is a Suppressor of Spontaneous Mammary Tumors in Mice.
Kartha N; Shen L; Maskin C; Wallace M; Schimenti JC
Genetics; 2016 Aug; 203(4):1601-11. PubMed ID: 27280691
[TBL] [Abstract][Full Text] [Related]
32. ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma.
Sato E; Nakayama K; Razia S; Nakamura K; Ishikawa M; Minamoto T; Ishibashi T; Yamashita H; Iida K; Kyo S
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29890703
[TBL] [Abstract][Full Text] [Related]
33. Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number.
Wang Q; Diskin S; Rappaport E; Attiyeh E; Mosse Y; Shue D; Seiser E; Jagannathan J; Shusterman S; Bansal M; Khazi D; Winter C; Okawa E; Grant G; Cnaan A; Zhao H; Cheung NK; Gerald W; London W; Matthay KK; Brodeur GM; Maris JM
Cancer Res; 2006 Jun; 66(12):6050-62. PubMed ID: 16778177
[TBL] [Abstract][Full Text] [Related]
34. Personalized genomic analyses for cancer mutation discovery and interpretation.
Jones S; Anagnostou V; Lytle K; Parpart-Li S; Nesselbush M; Riley DR; Shukla M; Chesnick B; Kadan M; Papp E; Galens KG; Murphy D; Zhang T; Kann L; Sausen M; Angiuoli SV; Diaz LA; Velculescu VE
Sci Transl Med; 2015 Apr; 7(283):283ra53. PubMed ID: 25877891
[TBL] [Abstract][Full Text] [Related]
35. MutComFocal: an integrative approach to identifying recurrent and focal genomic alterations in tumor samples.
Trifonov V; Pasqualucci L; Dalla Favera R; Rabadan R
BMC Syst Biol; 2013 Mar; 7():25. PubMed ID: 23531283
[TBL] [Abstract][Full Text] [Related]
36. IGF2BP1 harbors prognostic significance by gene gain and diverse expression in neuroblastoma.
Bell JL; Turlapati R; Liu T; Schulte JH; Hüttelmaier S
J Clin Oncol; 2015 Apr; 33(11):1285-93. PubMed ID: 25753434
[TBL] [Abstract][Full Text] [Related]
37. Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers.
Decock A; Ongenaert M; Hoebeeck J; De Preter K; Van Peer G; Van Criekinge W; Ladenstein R; Schulte JH; Noguera R; Stallings RL; Van Damme A; Laureys G; Vermeulen J; Van Maerken T; Speleman F; Vandesompele J
Genome Biol; 2012 Oct; 13(10):R95. PubMed ID: 23034519
[TBL] [Abstract][Full Text] [Related]
38. Epigenetic Targeting of
Huang M; Zeki J; Sumarsono N; Coles GL; Taylor JS; Danzer E; Bruzoni M; Hazard FK; Lacayo NJ; Sakamoto KM; Dunn JCY; Spunt SL; Chiu B
Cancer Res; 2020 Mar; 80(5):1024-1035. PubMed ID: 31900258
[TBL] [Abstract][Full Text] [Related]
39. Identification of a novel recurrent 1q42.2-1qter deletion in high risk MYCN single copy 11q deleted neuroblastomas.
Fieuw A; Kumps C; Schramm A; Pattyn F; Menten B; Antonacci F; Sudmant P; Schulte JH; Van Roy N; Vergult S; Buckley PG; De Paepe A; Noguera R; Versteeg R; Stallings R; Eggert A; Vandesompele J; De Preter K; Speleman F
Int J Cancer; 2012 Jun; 130(11):2599-606. PubMed ID: 21796619
[TBL] [Abstract][Full Text] [Related]
40. Telomerase activation by genomic rearrangements in high-risk neuroblastoma.
Peifer M; Hertwig F; Roels F; Dreidax D; Gartlgruber M; Menon R; Krämer A; Roncaioli JL; Sand F; Heuckmann JM; Ikram F; Schmidt R; Ackermann S; Engesser A; Kahlert Y; Vogel W; Altmüller J; Nürnberg P; Thierry-Mieg J; Thierry-Mieg D; Mariappan A; Heynck S; Mariotti E; Henrich KO; Gloeckner C; Bosco G; Leuschner I; Schweiger MR; Savelyeva L; Watkins SC; Shao C; Bell E; Höfer T; Achter V; Lang U; Theissen J; Volland R; Saadati M; Eggert A; de Wilde B; Berthold F; Peng Z; Zhao C; Shi L; Ortmann M; Büttner R; Perner S; Hero B; Schramm A; Schulte JH; Herrmann C; O'Sullivan RJ; Westermann F; Thomas RK; Fischer M
Nature; 2015 Oct; 526(7575):700-4. PubMed ID: 26466568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
